Background: The use of antibiotic therapy early in life might influence the risk of develop-
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| INTRODUCTION
Several environmental and genetic factors have been identified as risk factors for asthma and asthma exacerbations, [1] [2] [3] [4] including early life risk factors such as antibiotic exposure. However, previous studies have shown conflicting findings whether antibiotic exposure in early life increases the risk of asthma development in children. Furthermore, the association between early life antibiotic use and severity of asthma is not well studied. 5 The aim of this study was to evaluate the effect of early life antibiotic use on the risk of asthma onset later in life in the general population. Moreover, in the pediatric population with asthma, the association between early life antibiotic use and risk of asthma exacerbations later in life was studied.
| METHODS

| Study setting and population
To study the effect of antibiotic treatment early in life on asthma development, we used data from two population-based cohorts (Generation R 6 and SEATON 7, 8 ), and to assess the effect of early life antibiotic use on asthma exacerbations, we used data from two pediatric asthma populations (PACMAN 9 and BREATHE 10, 11 ). Generation R is a Dutch prospective population-based cohort study (n=7393) of children from fetal life until young adulthood. Detailed information on the design and methods of this study has been described previously. 6 SEATON is a Scottish birth cohort study (n=2000). Between 1997 and 1999, healthy unselected pregnant women attending an antenatal clinic, at median 11 weeks gestation, were recruited. In this study, singletons born to the recruited women were followed up for 10 years. 7, 8 PACMAN (n=995) is a Dutch cohort of 4-to 12-year olds on asthma medication, selected through Dutch community pharmacies. In this cohort, children with at least 2 years of dispensed medication data available and at least three prescriptions for any asthma drug within the last 2 years and at least one prescription in the last 6 months were selected from pharmacies in The Netherlands. 9 BREATHE is a Scottish cohort of children aged 3-19 years (n=1100) with physiciandiagnosed asthma recruited through primary or secondary clinics. The
Community Health Index (CHI) coding was available for the BREATHE participants, and data could be linked to several other databases, for example, community prescribing information and diagnosis of acute hospital admission. 10, 11 Within the four cohorts, questionnaire-based information was available on general health, allergic symptoms, asthma and respiratory symptoms, healthcare utilization for respiratory symptoms, environmental, and sociodemographic factors.
| Exposure
Antibiotic use in the Generation R cohort (first 3 years) and in the SEATON cohort (first 6 months) was available from parental-reported data. In PACMAN and BREATHE, pharmacy data were available from the 1st year of life, including detailed information on dispensed medication. In PACMAN and in BREATHE, ATC codes (listed in Table S1) and British National Formulary (BNF) codes (including all antibiotic in Chapter 5.1 of the BNF 12 ) were used. Date of dispensing, duration, and amount dispensed and doses were extracted from these databases. In case of missing values, duration of antibiotic was calculated by assuming a course of 7 days. Depending on the available information in the four databases, antibiotic use was classified as (i) exposed vs never exposed (in all four databases), (ii) the timing of the first antibiotic use: 1st year, the 2nd year, or the 3rd year of life (in Generation R, PACMAN, and BREATHE), (iii) the number of prescriptions for antibiotic during the first 3 years (PACMAN and BREATHE), and (iv) the total days of exposure to antibiotic during the first 3 years (PACMAN and BREATHE).
| Outcomes
Two outcomes were defined in this study: (i) physician-diagnosed asthma, defined as a positive response to the following questions at age of 9-10 years in Generation R and at age of 10 years in SEATON 'has your child ever suffered from asthma?' and 'was this confirmed by a doctor?', and (ii) asthma exacerbations, defined as asthma-related visits to an emergency department (ED) and/or the use of oral corticosteroids (OCS) in the past 12 months in PACMAN and asthma-related hospitalization and/or OCS use in the past 6 months in BREATHE. 13 As data on asthma control (measured with asthma control questionnaire (ACQ) were only available in PACMAN database, we were not able to study this outcome.
| Statistical analysis
Children with missing values on exposure and outcomes were excluded from data analyses. In all analyses, children exposed to antibiotic were compared with unexposed children. The estimates for the association between antibiotic use and asthma in the Generation R and SEATON cohorts were meta-analyzed using a fixed-or random-effect model.
In the Generation R cohort, we only used the 1st year of life of 
| RESULTS
In the population-based cohorts, 7393 children in Generation R and 891 of 2000 children in SEATON had data available on both exposure to antibiotic and respiratory outcome. In Generation R, the rate of early life exposure to antibiotic (1st year) was 55%, while in SEATON, this rate (first 6 months) was 29% (Table 1) . Cumulative incidence rates of asthma in Generation R and SEATON were 10% and 8%, respectively. In the asthma populations, 668 of 995 (PACMAN) and 806 of 1100 (BREATHE) children had pharmacy data available starting from the 1st year and were therefore included in this study.
In these two databases, 78% and 84% of children had at least one antibiotic prescription during the first 3 years, respectively. The rate of children with at least one asthma exacerbation varied between 12%
in PACMAN and 24% in BREATHE.
In the SEATON cohort, there were no statistically significant differences in baseline characteristics of children with and without missing data on early life antibiotic use except for family history of asthma (Table S2 ). When we compared the baseline characteristics of children who were lost to follow-up (unknown asthma diagnosis) with those included in the analyses, the results showed statistically significant difference in gender and family history of asthma between the two groups but not in exposure to antibiotics in early childhood (data not shown).
| Early life antibiotic use and asthma susceptibility
In the two population-based cohorts, pooled results showed that children who used antibiotic during the 1st year of life were stati- 
| Early life antibiotic use and asthma exacerbations
In (Table 3) .
The results of age-stratified logistic regression analyses showed no statistically significant differences between different age categories in the two asthma populations. However, in both studies, there seemed to be a trend toward a higher risk of asthma exacerbations in younger (4-6 years in PACMAN and 3-6 years in BREATHE) compared to older children (Table 4 ).
| DISCUSSION
In this study, we showed children who had been exposed to antibiotic early in life had a higher risk of developing asthma. However, asthmatic children who were exposed to antibiotic early in life did not have a higher risk of asthma exacerbations.
In recent decades, a rise in the proportion of children treated with antibiotic in early childhood has been reported; the highest rate of antibiotic use (18.7%) was shown in children aged >1 month to 18 years treated for a bacterial lower respiratory tract infection. 16 Due to a high burden of infections in children in the first years of life, the prescribing rate of antibiotic is high (in our study around 80%). When antibiotic use in early life indeed increases the risk of asthma, it would be important to be more critical about the prescription of antibiotic. Studies have shown that antibiotics are often prescribed inappropriately 17, 18 for indications for which antibiotics are not necessary like common cold and sinusitis caused by viral infections.
Our findings regarding a higher risk of asthma in children exposed to antibiotic at an early age are in line with previous studies. [19] [20] [21] [22] [23] In a very recent population-based birth cohort study of 143 000 children, a high risk of new-onset asthma was observed in children treated with antibiotic before the age of 12 months (incidence rate ratio: 1.51). 20 In the Generation R cohort, we showed that the strongest risk of asthma was in children exposed to antibiotic during the first year of life and the effect decreased if they were treated at an older age. Previous studies showed that the risk of asthma in children exposed to antibiotic in early life diminished with aging and was no longer statistically significant after 3 years of age. 21, 23 Our findings were also in line with the findings of a meta-analysis including 18 studies that reported a weak but statistically significant association between early life antibiotic exposure and the development of asthma (OR: 1.27, 95% CI:
1.12-1.43).
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A higher risk of asthma among children treated with antibiotic during early childhood could be explained in different ways. First, the immunomodulatory effect of antibiotic in which changes in the intestinal bacterial diversity during the first months of life influence the immune system, T helper, and regulatory T cell (Tregs) balance.
Evidence showed that modifiable factors such as gut microbiome and diet have a key role in the maturation of the neonatal immune system and thereby might also affect the risk of asthma and asthma exacerbations. 1, 24, 25 The healthy gut microbiome is highly diverse and can be disturbed by environmental factors, for example, antibiotic therapy.
Another explanation for the higher risk could be confounding by indication. It is possible that children who are in need of antibiotic early in life have already a Th1/Th2 imbalance caused by the infections Importantly, children in the PACMAN study were recruited through community pharmacies based on their regular use of medication for asthma treatment, while participants of the BREATHE were recruited through primary and secondary asthma clinics. Therefore, the children included in BREATHE might reflect a more severe asthma population who more often suffer from asthma exacerbations. Cultural differences in OCS prescriptions in different countries might also explain part of the discrepant results. However, the results of the association between antibiotic and asthma exacerbations were very similar in PACMAN and BREATHE; even though the point estimates were in opposite directions, the 95% CIs largely overlapped. A previous study reported a statistically significant positive association between antibiotic use and asthma exacerbations shortly after treatment with antibiotic (before the age 2 years), and not at older age. 5 The latter finding is in line with the findings in our study; however, we did not have data to study asthma exacerbations before the age of 2 years.
There are some potential limitations in this study that should be acknowledged. Importantly, our study was limited by the high rate of missing data in the three studies including SEATON (56%), PACMAN (33%), and BREATHE (27%). When assessing the baseline characteristics of the children with and without missing data, in SEATON cohort, the results showed no statistically significant differences in asthma development between children with and without missing data on antibiotic use in early childhood. Therefore, our study was not prone to selection bias. However, the results of analyses in the two asthma populations showed statistically significant differences in asthma exacerbations between the two groups in which those who had missing data on early life medications had remarkably less asthma exacerbations compared with those with available data in PACMAN (6.1% vs 12.3%, P=.003) and in BREATHE (11.6% vs 24.3%, P=.01). Therefore, this might have led to an overrepresentation of children with more severe asthma in the analyses. Generation R Ever exposed vs never exposed to antibiotic, n=7393
Ever exposed, n=3178 Another important limitation in this study was the heterogeneity in study designs. For example, the time periods for antibiotics exposure were not consistent in the two population based studies; the first 3 years in Generation R and the first 6 months in SEATON. Different time periods for antibiotics exposure (and therefore different age at time of antibiotic use) might have led to a stronger association in Generation R compared with SEATON study. In the asthma studies, antibiotic exposure could be defined based on pharmacy data, while these data were not available in the population-based studies. In these studies, the use of antibiotic was parental reported, and this definition might be more prone to recall bias.
The definition of asthma diagnosis in both Generation R and SEATON was based on a parental questionnaire. This might have led to misclassification of asthmatic children especially when the diagnosis was obtained at a young age or an under-reporting of asthma cases.
However, we previously showed that there is a high agreement (89%) between physician-diagnosis asthma and parental-reported asthma in the PACMAN study. 26 Heterogeneity in confounders involved in the adjusted models is another limitation. The associations in different populations were adjusted for different confounders based on available variables in each F I G U R E 2 Pooled odds ratio of the associations between early life exposure to antibiotics and asthma exacerbations, using fixed-effect model study. Lack of consistent adjustment in the present study might have influenced the associations; the possibility remains that some factors which were not measured in every population caused confounding.
The present study was also limited by the lack of availability of potential confounders such as genetic factors, socioeconomic status, and infections/siblings. In none of the databases, we had information about the indications for the prescribing of antibiotic.
In summary, our findings show a higher risk of asthma in children who are treated with antibiotic early in life, but no association of early life antibiotic use and asthma exacerbations later in asthmatic children.
We propose that further research is needed to explore the effects of antibiotic on the immune system and gut microbiome in the pathogenesis of asthma.
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